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INTRODUCTION 
Diseases that affect podocytes typically present with pro-
teinuria, with or without nephrotic syndrome. However, it
should be noted that not all cases with nephritic range pro-
teinuria are caused by podocyte diseases, because the glomeru-
lar filtration barrier also contains glomerular endothelial cells
and glomerular basement membrane (GBM) (1). Moreover,
fixed anionic charges on glomeruli are believed to form an
important component of the glomerular filtration barrier. Thus
several studies have been reported that the changes of anion-
ic sites of the GBM might cause proteinuria (2-4). These stud-
ies suggest that proteinuria can be induced by a combination
of various factors, i.e., both structural and functional factors,
and that it can be reduced by addressing the factors concerned.
Nonsteroidal anti-inflammatory drugs (NSAIDs) actively
inhibit both cyclooxygenases (COX-1 and COX-2), and there-
by block prostaglandin production. Anti-proteinuric effect
of NSAIDs in nephrotic syndrome is presumed to be due to
reductions in renal plasma flow and glomerular filtration rates.
Nevertheless, their use is limited by various side effects caused
by COX-1 inhibition. Therefore the therapeutic applications
of selective COX-2 inhibitor might result in more selective
inhibition of inflammatory processes without influencing basal
COX-1-dependent prostaglandin synthesis (5, 6). 
The 5-lipoxygenase (LOX) inhibitor, nordihydroguaiaret-
ic acid (NDGA), is a typical lignin found in the creosote bush
(Larrea tridentata or Larrea divarita) which has a worldwide
distribution. These plants are used as traditional medicines
for more than 50 illnesses, including rheumatism, diabetes,
gallbladder and kidney stones, and sterility (7). LOX inhibitors
have also been compared with other NSAIDs, COX inhibitors,
and leukotriene inhibitors in terms of their anti-inflammato-
ry, anti-thrombotic, and anti-platelet effects (8, 9). Recently
it was reported that NDGA could reverse the oxidative stress,
and reduce proteinuria in diabetic nephropathy rats (10).
Therefore we hypothesized that proteinuria might be relat-
ed to both the COX and LOX pathways. The present study
was designed to investigate the therapeutic efficacy of NDGA
as compared with celecoxib in puromycin aminonucleoside
(PAN) nephrosis rats.
MATERIALS AND METHODS
Animals
Fifty five male Sprague-Dawley rats, which initially weighed
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Effects of Celecoxib and Nordihydroguaiaretic Acid on Puromycin
Aminonucleoside-Induced Nephrosis in the Rat
The selective cyclooxygenase-2 (COX-2) and 5-lipoxygenase (LOX) inhibitors might
inhibit prostaglandin synthesis and reduce proteinuria. The present study was designed
to investigate the anti-proteinuric effects of nordihydroguaiaretic acid (NDGA) as
compared with celecoxib in puromycin aminonucleoside (PAN) nephrosis rats. Fifty
five male Sprague-Dawley rats were divided into 4 groups; A, normal control; B,
PAN group; C, PAN+COX-2 inhibitor (celecoxib) group; and D, PAN+5-LOX inhibitor
(NDGA) group. After induction of PAN nephrosis through repeated injections of PAN
(7.5 and 15 mg/100 g body weight), rats were treated with celecoxib, NDGA, or vehi-
cle for 2 weeks. Twenty four hour urine protein excretions were significantly lower in
PAN+celecoxib and PAN+NDGA groups than in PAN group. Serum creatinine (SCr)
concentrations and 24 hr urine creatinine clearances (CCr) were not significantly
different in the four groups. Electron microscopy showed that podocyte morphology
was changed after the induction of PAN nephrosis and was recovered after celecox-
ib or NDGA administration. Celecoxib significantly recovered the expressions of nephrin,
CD2AP, COX-2, and TGF-β . NDGA also recovered TGF-βexpression, but did not
alter the expressions of nephrin, CD2AP and COX-2. The present study suggest-
ed that celecoxib and NDGA might effectively reduce proteinuria in nephrotic syn-
drome without impairing renal function.
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Accepted : 25 November 2008250-300 g, were kept in individual metabolic cages with free
access to standard chow and water. The rats were divided into
4 groups; A (n=10), normal control; B (n=15), PAN group;
C (n=15), PAN+celecoxib group; and D (n=15), PAN+
NDGA group. They were subjected to standard laboratory
tests for 4 weeks before being sacrificed for kidney removal.
All experiments were performed in accordance with the NIH’s
Guiding Principles in the Care and Use of Laboratory Animals.
Drugs and reagents
PAN (6-dimethylamino-9[3′ amino-3′ -deoxyribosyl]purine,
Sigma Chemical Co., St. Louis, MO, U.S.A.) was prepared
for i.p. injection (7.5 and 15 mg/100 g body weight). Cele-
coxib (Celebrex
�, Pfizer Inc., Seoul, Korea) was dissolved in
drinking water for gavage (4 mg/100 g body weight/day).
NDGA (Sigma Chemical Co.) was prepared in dimethyl sul-
foxide (DMSO, Sigma Chemical Co.) solution for s.c. injec-
tion (1 mg/100 g body weight/day). All drugs administered
i.p. or s.c. were prepared in a constant volume (0.1 mL/100 g
body weight) at the beginning of each experiment.
Treatment schedule
After 3 days of acclimation, rats were injected i.p. with
PAN 7.5 mg/100 g body weight (day 0), and then with 15
mg/100 g body weight 7 days later (day 7). Control animals
received an identical volume of vehicle. On day 14, serum and
24 hr urine samples were obtained to confirm the onset of
proteinuria in the nephrotic range.
After the induction of PAN nephrosis, rats were treated
with celecoxib, NDGA, or vehicle from day 14 to 27. Fifteen
nephrotic rats were gavaged daily with celecoxib (4 mg/100 g
body weight/day), 15 were injected s.c. daily with NDGA
(1 mg/100 g body weight/day), and 15 were injected s.c. with
vehicle. Ten control rats were also injected s.c. with vehicle.
On days 21 and 28, serum and 24 hr urine samples were
obtained to determine blood and urine chemistries. Twenty
four hour urine creatinine clearances (CCr) was used as surro-
gate of glomerular fitration rate (GFR) (Fig. 1).
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All values are expressed in mean±SD. *p<0.05 vs. group A, 
� p<0.05 vs. group B.
PAN, puromycin aminonucleoside; NDGA, nordihydroguaiaretic acid.
Group A (normal controls) Group B (PAN) Group C (PAN+Celecoxib) Group D (PAN+NDGA)
Serum albumin (mg/dL)
Day 7 1.6±0.1 1.3±0.4 1.0±0.2 1.1±0.1
Day 14 1.4±0.1 1.3±0.4 1.2±0.4 1.2±0.2
Day 21 1.5±0.2 1.8±0.2 1.6±0.4 1.7±0.1
Day 28 1.5±0.4 1.3±0.4 1.2±0.3 1.1±0.2
24 hr urine protein (mg/dL)
Day 7 63.7±22.5 57.8±22.6 57.6±22.4 45.4±20.2
Day 14 53.4±22.6 253.2±95.8* 298.6±69.9* 183.7±80.7*
Day 21 44.6±20.5 619.1±132.3* 653.6±185.6* 672.9±61.8*
Day 28 55.1±26.5 704.4±225.7* 177.4±119.9
� 254.2±207.2
�
Serum creatinine (mg/dL)
Day 7  0.57±0.16 0.89±0.18 0.94±0.22 0.97±0.19
Day 14 0.59±0.23 0.56±0.05 0.58±0.09 0.59±0.12
Day 21 0.63±0.10 0.47±0.07 0.57±0.13 0.47±0.05
Day 28 0.60±0.16 0.40±0.06 0.59±0.25 0.44±0.05
24 hr urine creatinine clearance (mL/min)
Day 7 1.12±0.27 0.74±0.36 0.68±0.21 0.58±0.20
Day 14 1.43±0.74 1.60±0.35 1.46±0.44 1.14±0.26
Day 21 1.38±0.55 2.25±0.97 1.87±0.55 1.95±0.33
Day 28 1.36±0.48 2.61±0.92 2.28±1.04 2.31±0.33
Table 1. Changes in serum and 24 hr urine parameters in the four experimental groups
Fig. 1. Schematic of the treatment schedule. After three days of
acclimation, test animals were injected intraperitoneally on day 0
with PAN 75 mg/kg, and then 7 days later with 150 mg/kg. Control
animals were administered an identical volume of normal saline.
After inducing PAN nephrosis, all animals were treated with cele-
coxib (40 mg/kg/day), NDGA (10 mg/kg/day), or vehicle up to Day
28. Serum and 24 hr urine samples were obtained on days 0, 7,
14, 21, and 28 ( ). All rats were sacrificed on day 28, and kidneys
were removed immediately for histological examinations.
Normal controls
PAN
PAN+celecoxib
PAN+NDGA
Induction of
PAN nephrosis Celecoxib
Vehicle
Day -3 0 7 14 21 28
PAN PAN Nephrectomy
7.5 mg/100 g 15 mg/100 g
Vehicle Saline
Accli-
mation
NDGAKidney tissue preparation
On day 28, all rats were sacrificed under general anesthe-
sia using i.p. injection of ketamine. Kidneys were removed
immediately for histological examinations and for isolation of
glomeruli. Kidney sections were fixed in 10% neutral-buffered
formalin, blocked in paraffin wax, and stained with hema-
toxylin-eosin (H&E) and periodic acid-Schiff (PAS) reagent.
To evaluate glomerular sclerotic changes, we observed at least
100 glomeruli in each section. For electron microscopy, kid-
ney sections were fixed in 2.5% glutaraldehyde, postfixed in
1% osmium, and embedded in epoxy resin. Ultrathin sections
were stained with uranyl acetate.
Isolation of glomeruli and reverse transcription-PCR
Rats were perfused through left ventricles with saline. Kid-
neys were removed and cortices were finely minced, sieved
through sequential sieves, and digested in collagenase. Total
glomerular RNA was extracted using TRIzol
� (Invitrogen,
Carlsbad, CA, U.S.A.). The levels of the mRNAs of nephrin,
CD2AP, COX-2, and TGF-βwere determined by reverse tran-
scriptase-polymerase chain reaction (RT-PCR) using PCR Pre-
Mix
� (Bioneer, Daejeon, Korea) using the primers shown in
Table 2.
Statistical analyses
All values are presented as means±SD. Repeated measures
ANOVA and post-hoc analysis (Tukey test) were used for the
analysis, and differences were considered significant when p
values were <0.05.
RESULTS
Effects of celecoxib and NDGA on proteinuria
On day 7, seven days after the first PAN (7.5 mg/100 g
body weight) injection, all rats in the treatment groups showed
physiological proteinuria (63.7±22.5, 57.8±22.6, 57.6±
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Gene Direction Sequence Size
GAPDH Forward GGCGTCTTCACCACCATGGAG 477
Reverse GCCTGCTTCACCACCTTCTTG
Nephrin Forward AGCCTCTTGACCATCGCTAA 293
Reverse GTCCTCGCCTTCAGCACCTG
CD2AP Forward CCAGCTCCAAAACCTGACC 496
Reverse GGGTTGGAGAATGTCCACC
COX-2 Forward CCAGTATCAGAACCGCATTGC 464
Reverse CAAGTTCTACCATGGTCTCCC
TGF-β 1 Forward CAACAATTCCTGGCGATACC 468
Reverse GCTCCAAATGTAGGGGCAGGG
Table 2. Sequences of PCR primers
Fig. 2. Effects of celecoxib and NDGA on 24 hr urine protein excre-
tion in PAN-induced nephrosis rats. Twenty four hour urine protein
excretion amounts were significantly lower in groups C and D on day
28 than in group B (*p<0.05 vs. group B). Group A, normal controls;
group B, a PAN group; group C, a PAN+celecoxib group; group
D, a PAN+NDGA group. 
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Fig. 3. Representative pathologic features of a PAN and a PAN+
celecoxib groups. (A) Light microscopic feature of a glomerulus in
PAN group. Small segmental proliferations with matrix expansion
and adhesions between the glomerular tuft and Bowman’s capsule
were observed (PAS stain, ×300). (B) Electron microscopic fea-
ture of mild foot processes changes (arrow) such as effacement,
fusion and microvilli in PAN group. (C) Light microscopic feature
of a glomerulus in PAN+celecoxib group. Slight expansion of mes-
angial matrix was observed (PAS stain, ×300). (D) Electron micro-
scopic feature of non-specific foot processes changes in PAN+
celecoxib group.
A B
C D22.4, and 45.4±20.2 mg/24 hr, respectively) and increased
weights (353.6±23.4, 338.6±28.8, 353.6±10.7, and 349.3
±20.9 g, respectively) versus their baseline weights (279.3
±10.6, 274.3±10.6, 291.4±8.0, and 290.7±12.4 g, res-
pectively).
On day 14, seven days after the second PAN (15 mg/100 g
body weight) injection, rats in groups B, C, and D exhibited pro-
teinuria in the nephrotic range of 253.2±95.8, 298.6±69.9,
and 183.7±80.7 mg/24 hr, whereas rats in group A showed
physiological proteinuria of 63.7±22.5 mg/24 hr (p<0.05 vs.
group A). Mean serum albumin concentrations in groups B,
C, and D tended to be lower 1.3±0.4, 1.2±0.4, and 1.2±
0.2 g/dL, respectively, than in group A 1.4±0.1 g/dL.
On day 21, seven days after initiating celecoxib and NDGA
treatment, group C and D rats still showed elevated levels
of proteinuria (653.6±185.6 and 672.9±61.8 mg/24 hr,
p<0.05 vs. group A). 
On day 28, group C and D rats exhibited significant reduc-
tions in proteinuria (177.4±119.9 and 254.2±207.2 mg/
24 hr), whereas group B rats showed a further increase in pro-
teinuria (704.4±225.7 mg/24 hr, p<0.05 group C vs. group
B and group D vs. group B, Table 1, Fig. 2). 
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Fig. 4. Effects of celecoxib and NDGA on nephrin, CD2AP, COX-2, and TGF-β mRNA expressions. (A) Nephrin mRNA expressions decreased
after administering PAN in PAN group, and restored significantly in PAN+celecoxib group. (B) CD2AP mRNA expressions decreased in
PAN group, and restored significantly in PAN+celecoxib group. (C) COX-2 mRNA expressions increased in PAN group, and restored
significantly in PAN+celecoxib group. (D) TGF-βmRNA expressions increased in PAN group, and decreased significantly in PAN+cele-
coxib and PAN+ NDGA groups. *p<0.05 vs. normal controls; 
� p<0.05 vs. PAN group.
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�Effects of celecoxib and NDGA on renal functions
In groups C and D, SCr tended to decrease, and 24 hr urine
CCr to increase. However there were no significant changes
during the experiment (p>0.05, Table 1).
Effects of celecoxib and NDGA on renal morphology
Light microscopy revealed small segmental proliferations
with matrix expansion and adhesions between the glomeru-
lar tuft and Bowman’s capsule in group B, C, and D. How-
ever, focal segmental or global sclerotic lesions were not ob-
served. Electron microscopy revealed variable degrees of foot
processes fusion, effacement, and microvillous transformation
in group B, but not in groups C and D on day 28 (Fig. 3).
Effects of Celecoxib and NDGA on the expressions of
nephrin, CD2AP, COX-2, and TGF-β β
PAN significantly reduced the expressions of nephrin and
CD2AP, and increased the expressions of COX-2 and TGF-β
(p<0.05 vs. group A, respectively). However, celecoxib sig-
nificantly restored the expressions of nephrin, CD2AP, COX-
2, and TGF-β(p<0.05 vs. group B, respectively). NDGA also
restored TGF-βexpression (p<0.05 vs. group B), but did not
alter the expressions of nephrin, CD2AP and COX-2 (Fig. 4).
DISCUSSION
The PAN nephrosis model used in the present study, is a
well-described animal model of human idiopathic nephrotic
syndrome, and has been used extensively to study the fun-
damental processes of proteinuria (11-13). PAN is a nephro-
toxin and may injure podocytes and alter the selectivity of
the GBM. However, the precise mechanisms that underlie
PAN-induced proteinuria are not well understood. 
Sprague-Dawley rats that were injected with a single dose
of PAN developed significant proteinuria several days later.
In PAN-induced nephrosis, the onset of proteinuria coincides
with the development of focal defects in podocyte epithelium,
which expose the outer surface of the GBM to the urinary
space (14, 15). However these morphological and functional
changes are recovered within 1-2 weeks after the induction
of PAN nephrosis. Recent studies showed that the repeated
injections of PAN induced specific focal glomerulosclerosis
lesions, but with an incidence of only 10-30% (16-19). There-
fore we attempted to repeat injections twice with an interval
of seven days to maintain the proteinuria in the nephrotic range
with the absence of self-reduction over the course of the exper-
iments. In the present study, after the first PAN injection (7.5
mg/100 g body weight), no significant increase in protein-
uria was observed, but the second injection (15 mg/100 g body
weight) induced a significant and sustained increase in pro-
teinuria over a period of two weeks. However, no glomeru-
losclerotic lesions were found in the present study. 
In models of progressive glomerular injury, COX-2 inhibitors
decrease proteinuria and retard progressive glomerulosclero-
sis (20-22). LOX inhibitors have also been studied as poten-
tial anti-inflammatory agents with anti-thrombotic and anti-
platelet effects (8, 9). In the present study, anti-proteinuric
effects of celecoxib and NDGA suggest that hemodynamic
improvements are associated with eicosanoids in the arachi-
donic acid pathway, and with anti-inflammatory and immune
modulating effects. On the contrary to the previous reports,
our study showed the sustained increase in 24 hr urine CCr
in PAN-treated groups (B, C, and D). These findings are th-
ought to be the results of hyperfiltration in the early stage of
acute kidney injury caused by PAN injections. LOX inhibitors
have been reported to have protective effects on ileal motor
disturbances induced by endotoxins, to promote adaptation
following massive bowel resection, and to promote correction
of coronary spasms of immune origin (23-25). These findings
suggest that LOX inhibitors can reduce proteinuria due to
their anti-inflammatory and protective effects on vascular sm-
ooth muscle.
PAN causes podocyte injury and reduces the expressions
of nephrin and CD2AP. In the present study, celecoxib restored
the expressions of nephrin and CD2AP, but NDGA did not
alter their expressions. Furthermore, whereas celecoxib restored
COX-2 expression, NDGA increased it through complemen-
tary enhancing the COX pathway. It appears that overexpres-
sion of COX-2 by NDGA predisposed podocyte injury, which
negated its beneficial anti-inflammatory effect (26). PAN
caused focal mesangial expansion and fibrosis, and increased
the expression of TGF-β . TGF-βcan cause extracellular matrix
(ECM) accumulation by enhancing the productions of colla-
gen and fibronectin by glomerular mesangial cell, by suppress-
ing the expression of ECM-degrading protease, and by increas-
ing the synthesis of ECM protease inhibitors (27-29). In this
study, we found that celecoxib and NDGA reduced TGF-β
expression, which suggests the possible involvements of the
COX and LOX pathways in TGF-β -induced ECM accumu-
lation and proteinuria.
In conclusion, our results support the involvements of the
COX and LOX pathways in PAN-induced proteinuria. Cele-
coxib and NDGA could reduce proteinuria without impair-
ing renal function, by promoting hemodynamic and anti-in-
flammatory improvements. In particular, celecoxib might
reduce proteinuria, restore the expressions of nephrin and
CD2AP, and suppress the expressions of COX-2 and TGF-β .
Further investigations should be conducted to elucidate the
roles of these pathways in the pathogenesis of proteinuria, as
this would help identify the anti-proteinuric effects of cele-
coxib and NDGA in progressive glomerular disease. 
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